Respiratory testing guidance is in continuous revision, and each revision ripples into platform strategy, assay menus, and laboratory capacity planning. One principle recurs across the guidance teams are usually asked to follow: wider multiplexing where results change management, targeted and rapid testing where they do not, and closer attention to how multi-target results are interpreted and acted on. For laboratories and the distributors who supply them, three implications deserve standing attention.
Multiplex or targeted: follow the management decision
The durable principle in current guidance is that panel breadth should be justified by the decision the result informs. For hospitalised and immunocompromised patients, where a broad differential genuinely changes isolation, cohorting, and therapy, syndrome-level multiplex panels are increasingly the expected standard — and paediatric admissions in particular argue for breadth, since the differential spans viral and atypical bacterial targets whose distinction changes management. In outpatient and seasonal settings the calculus inverts: a rapid, focused result on the two or three targets that trigger antiviral or public-health action outperforms a broad panel whose additional findings generate workups rather than decisions. Reviewers have also sharpened expectations around low-prevalence targets on large panels — findings at the margin of prevalence demand documented interpretation pathways, not merely a detected flag. The platform strategy that follows is two-tier by design: breadth where decisions need it, speed where they do not.
Plan capacity for the season, not the month
Respiratory demand is seasonal with real amplitude, and capacity decisions made against annual averages fail in the tenth week of a bad season. Plan the season deliberately: validate extended panels and any new assays before the season starts rather than during it, since mid-season validation competes for the same senior staff as the workload surge; stock reagent lots against a modelled peak rather than a rolling average, including the extended-shelf-life lots suppliers offer for pre-season commitments; and publish turnaround targets that are honest about seasonal load — a laboratory that promises off-season turnaround year-round will break the promise publicly in January. Staffing plans should identify the surge pool in advance, with competency documentation completed before the season, not during it. Distributors carry the mirror-image obligation: seasonal demand is a supply-chain commitment to be evidenced, not a forecast to be hoped at.
What evolving review expectations mean
For multi-target devices the burden is evidentiary: each individual target needs support of its own, not only the panel headline — analytical performance and clinical grounding per target, plus pre-specified handling of targets whose prevalence may not sustain standalone claims. Interpretation and reporting expectations increasingly require that panel results map to actionable categories, which pushes laboratories and suppliers toward clearer result-reporting design. And the stewardship conversation has arrived in diagnostics: guidance bodies show growing interest in how testing menus and algorithms support judicious antiviral and antibiotic use, which links assay selection to prescribing policy rather than treating them as separate documents. None of these shifts favours a particular vendor or chemistry, but all of them reward portfolios whose breadth is matched by evidence, and penalise menus assembled by accumulation.